Wells Fargo & Company Catalyst Pharmaceuticals, Inc. Transaction History
Wells Fargo & Company
- $434 Billion
- Q3 2024
A detailed history of Wells Fargo & Company transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 155,931 shares of CPRX stock, worth $3.42 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
155,931
Previous 39,184
297.95%
Holding current value
$3.42 Million
Previous $606,000
411.39%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding CPRX
# of Institutions
327Shares Held
94.6MCall Options Held
19.1KPut Options Held
51.1K-
Black Rock Inc. New York, NY18.7MShares$410 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.04MShares$176 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY6.23MShares$137 Million2.3% of portfolio
-
State Street Corp Boston, MA5.69MShares$125 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3.02MShares$66.2 Million0.01% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.25B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...